January 2025 in “Figshare” Compound glycyrrhizin with conventional treatments is effective and safe for promoting hair regrowth in alopecia areata.
Human placental extract effectively and safely improves melasma, ulcers, and alopecia areata.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
January 2025 in “International Journal of Dermatology Research” Higher MPV and CRP levels may indicate more severe alopecia areata.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
November 2024 in “Journal of Investigative Dermatology” Certain NK cell changes in blood may indicate alopecia areata progression.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
October 2024 in “The Journal of Dermatology” Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
Changes in skin bacteria may relate to alopecia areata severity.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
September 2024 in “Journal of the American Academy of Dermatology” Microneedling mildly regrows hair in androgenetic alopecia but not in other types.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
June 2024 in “Zagazig University Medical Journal” Intralesional vitamin D is mildly effective for treating Alopecia Areata.
June 2024 in “JEADV Clinical Practice” Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
Monthly PRP therapy is more effective than daily minoxidil for alopecia areata.
June 2024 in “IP Indian journal of clinical and experimental dermatology” PRP therapy effectively treats alopecia areata and atrophic acne scars.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
March 2024 in “Homœopathic Links” Phosphorus homeopathy treatment led to complete hair regrowth in two Alopecia Areata patients.
January 2024 in “Medicine” Hypothyroidism is often linked to the hair loss condition telogen effluvium.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.